Elevance Health Inc.

▲ Bull Case

• ◆MLR normalizes 86-87% + Carelon 6.0% + Star ratings windfall $2.5B: CMS rates offset MA utilization; star ratings change eliminates Stars-cycle overhang; Carelon hits management target 1 year early; adj. EPS $31; P/E re-rates to 18x (UNH-lite premium): $558 (+41%)
• ◆BCBS franchise premium fully recognized: Investors re-rate ELV's BCBS territorial moat (14-state exclusivity) as geographic monopoly rather than generic MCO; P/E premium to CVS/Cigna widens from 2-3x to 4-5x; adj. EPS $30; P/E 20x = $600 (+52%)
• ◆Carelon demerger optionality unlocked: If Carelon separated as standalone health services company (like UNH Optum valuation model), Carelon alone at 20x P/E on $4.7B normalized earnings = $94B—exceeding ELV's entire current market cap; pure optionality not priced in base case

▼ Bear Case

• ◆MLR structural at 90%+—MA cost inflation permanently higher: Post-COVID acuity permanently elevated in MA population; CMS rates chronically inadequate; MLR floor is 90% not 87%; adj. EPS $20 FY2027; P/E 13x (persistent underperformance): $260 (-34%)
• ◆Carelon margin plateaus at 4.8%—vertical integration not working: Pharmacy, behavioral, home care integration creates operational complexity with no margin improvement; goodwill write-down possible; market re-rates as pure-play insurer without service premium; adj. EPS $22; P/E 13x = $286 (-28%)
• ◆MA exit forced at scale + LT Debt $30.9B pressure: Continued MA losses force accelerated market exits; revenue loss triggers covenant review; dividend cut; adj. EPS $14; P/E 11x: $154 (-61%)

“Is ELV's MLR crisis cyclical (CMS rates lag → reset → recovery) or structural (MA population permanently sicker post-COVID, permanently elevating the MLR floor)? Bull view: MLR crisis is textbook managed care cyclicality—CMS rates are set in advance and lag actual cost trends 12-24 months; every MCO cycle ends the same: costs spike → CMS adjusts → margins recover. CMS 2027 rate +2.5% + star ratings windfall is the rate reset the cycle requires. BCBS territorial moat = captive insurer with pricing power; MLR 90% → 87-88% in 2 years consistent with every prior cycle. Bear view: COVID shock changed MA population mix permanently. Deferred procedures now being utilized at high rates; chronic disease costs permanently elevated in 65+; behavioral health costs structurally higher post-COVID. LT Debt spike $24.9B → $30.9B suggests balance sheet stretched by losses. If MLR floor is 90%, ELV at 14-16x FY2027E EPS is fairly valued not cheap. Our view: Cyclical thesis more likely (60-65% probability) based on CMS rate history and implemented regulatory changes. However, management credibility eroded from 3 guidance cuts in 2 years—market rationally applies credibility discount. At $395, discount is partially but not fully priced. ACCUMULATE; BUY below $350 where margin of safety is adequate.”

• ◆Q2 2026 MLR reading <90% (Aug 2026)—most critical near-term catalyst; confirms vs. denies recovery trajectory
• ◆CMS star ratings windfall for CY2027 (FY2027 revenue integration)—~$1.9-2.8B ELV share is regulatory fact, not forecast; April 2026 CMS rule change essentially locked in
• ◆FY2027 initial guidance (Feb 2027)—management credibility restoration trigger; need ≥$25 adj. EPS guide to stabilize narrative
• ◆Q3-Q4 2026 MLR trend confirmation (Oct/Feb)—validates whether Q2 recovery is durable or temporary
• ◆Carelon margin disclosure >5.5% (Q3-Q4 2026)—validates vertical integration thesis and management's margin expansion credibility

• ◆MLR structural at 90%+: Post-COVID acuity permanently higher in MA population; CMS rates chronically lag medical trend; MLR floor may not normalize to historical 85-87%. Probability 25%, Severity High.
• ◆Management credibility exhaustion: 4th consecutive guidance cut would trigger severe de-rating; market will not grant benefit of doubt. Probability 25%, Severity Moderate.
• ◆Carelon margin plateau: Vertical integration failing to deliver expected 6.5% target margin; complexity without payoff; goodwill write-down risk. Probability 30%, Severity Moderate.
• ◆CMS 2028 rate notice adverse: If 2028 rate <2% while medical costs +5-7%, bear case re-activated and MLR crisis repeats. Probability 15%, Severity High.
• ◆LT Debt $30.9B covenant pressure: Elevated leverage constrains capital allocation; dividend cut or covenant breach possible if earnings don't recover as expected. Probability 15%, Severity Moderate.